Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations

Pharmacotherapy

Volumn 23, Issue 5, 2003, Pages 572-578

  Cleary, John D ^a   Rogers, P David ^a   Chapman, Stanley W ^b,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN A; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; APOTHECON; GENSIA; INTERLEUKIN 1BETA; NYSTATIN; PHARMA TEK; PHARMACIA; POLYENE; VHA;

ANALYSIS OF VARIANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG PURITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MONONUCLEAR CELL; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; UNIVERSITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCHOLIC ACID; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-1; MONOCYTES; POLYENES; SPECTROPHOTOMETRY;

EID: 0038370094     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.5.572.32209     Document Type: Article

References (17)

1. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
2. Cleary JD, Chapman SW, Brown C. Cytokines as markers for amphotericin B adverse reactions. Presented at the 17th annual meeting of the American College of Clinical Pharmacy, St. Louis, MO, July 31-August 3, 1994.
3. Korzybski T, Kowszyk GZ, Kurylowicz W. Antifungal antibiotics (polyenes). In: Korzybski T, ed. Antibiotics: origin, nature and properties. Oxford: Polish Scientific Publishers, 1967:769-820.
4. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
5. Cleary JD, Chapman SW, Deng J, Lobb CJ. Amphotericin B enzyme-linked immunosorbent assay. Antimicrob Agents Chemother 1996;40:637-41.
6. Cleary JD, Nolan R, Chapman SW. Inhibition of interleukin 1 release from endotoxin or amphotericin B stimulated monocytes. Antimicrob Agents Chemother 1992;36:977-81.
7. Gelfand JA, Kimball K, Burke JF, Dinarello CA. Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1 [abstr]. Clin Res 1988;3:456A.
8. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever production by infusion amphotericin B. J Infect Dis 1987;156:784-9.
9. Chia JKS, Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis 1989;159:113-16.
10. Rogers PD, Jenkins JK, Chapman SW, Ndebele K, Chapman BA, Cleary JD. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 1998;178:1726-33.
11. Rogers PD, Kramer RE, Chapman SW, Cleary JD. Amphotericin B-induced IL-1β expression in human monocytic cells is calcium and calmodulin dependent. J Infect Dis 1999;180:1259-66.
12. Asher IM, Schwartzman G, for the U.S. Standard Antibiotics Research Group. Amphotericin B. In: Florey K, ed. Analytical profiles of drug substances. New York: Academic Press, 1977:1-42.
13. Hamilton-Miller JM. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev 1973;37:166-96.
14. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18.
15. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC collaborative study group. Clin Infect Dis 2000;31:1155-63.
16. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-8.
17. Kauffman CA, Wiseman SW. Anaphylaxis upon switching lipid-containing amphotericin B formulations. Clin Infect Dis 1998;26:1237-8.